Joseph N. Contessa, Ph.D.
Affiliations: | 2002 | Virginia Commonwealth University, Richmond, VA, United States |
Area:
Molecular Biology, Cell Biology, Medical Biophysics, OncologyGoogle:
"Joseph Contessa"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Rupert Schmidt-Ullrich | grad student | 2002 | VCU | |
| (Erb -B receptor -mediated survival mechanisms to ionizing radiation in carcinoma cells.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Wong SJ, Torres-Saavedra PA, Saba NF, et al. (2023) Radiotherapy Plus Cisplatin With or Without Lapatinib for Non-Human Papillomavirus Head and Neck Carcinoma: A Phase 2 Randomized Clinical Trial. Jama Oncology |
| Petrulli JR, Zheng M, Huang Y, et al. (2021) Evaluation of quantitative modeling methods in whole-body, dynamic [C]-erlotinib PET. American Journal of Nuclear Medicine and Molecular Imaging. 11: 143-153 |
| Baro M, Lopez Sambrooks C, Burtness BA, et al. (2019) Neuregulin Signaling is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma. Molecular Cancer Therapeutics |
| Klaver E, Zhao P, May M, et al. (2019) Selective inhibition of N-linked glycosylation impairs receptor tyrosine kinase processing. Disease Models & Mechanisms |
| Lopez Sambrooks C, Baro M, Quijano A, et al. (2018) Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors. Cancer Research |
| Baro M, Lopez Sambrooks C, Quijano A, et al. (2018) Oligosaccharyltransferase inhibition Reduces Receptor Tyrosine Kinase Activation and Enhances Glioma Radiosensitivity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Petrulli JR, Hansen SB, Abourbeh G, et al. (2017) A multi species evaluation of the radiation dosimetry of [(11)C]erlotinib, the radiolabeled analog of a clinically utilized tyrosine kinase inhibitor. Nuclear Medicine and Biology. 47: 56-61 |
| Magnuson WJ, Lester-Coll NH, Wu AJ, et al. (2017) Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016697144 |
| Lopez-Sambrooks C, Shrimal S, Khodier C, et al. (2016) Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells. Nature Chemical Biology |
| Magnuson WJ, Amini A, Patil T, et al. (2016) Deferring Radiation Therapy for Brain Metastases in Patients With EGFR-Mutant Non-Small Cell Lung Cancer: A Multi-Institutional Analysis. International Journal of Radiation Oncology, Biology, Physics. 96: S57-S58 |